Research programme: OX40/TRAIL fusion protein - KAHR MedicalAlternative Names: KAHR-104
Latest Information Update: 16 Jul 2016
At a glance
- Originator KAHR Medical
- Class Proteins
- Mechanism of Action OX40 ligand modulators; T lymphocyte inhibitors; TNF related apoptosis inducing ligand receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Israel